benzbromarone has been researched along with Diabetes Mellitus, Adult-Onset in 5 studies
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| " This study aims to investigate the possible influence of orally administered low- and high-dose glimepiride (GLM) on pharmacokinetic characteristics (PK) of benzbromarone (BNR) in rats." | 1.91 | Effects of different doses glimepiride intake on the pharmacokinetics of benzbromarone in rats. ( Chen, Z; Gu, X; Lin, Y; Liu, J; Wang, Y; Weng, Q; Xiong, J; Xu, H; Yu, Y, 2023) |
| "Gout is independently associated with increased risk of type 2 diabetes mellitus (T2DM)." | 1.51 | Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. ( Chang, HW; Lan, YC; Lin, MH; Lin, YW; Wang, RY, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, Y | 1 |
| Gu, X | 1 |
| Liu, J | 1 |
| Weng, Q | 1 |
| Xiong, J | 1 |
| Chen, Z | 1 |
| Yu, Y | 1 |
| Xu, H | 1 |
| Wang, Y | 1 |
| Chang, HW | 1 |
| Lin, YW | 1 |
| Lin, MH | 1 |
| Lan, YC | 1 |
| Wang, RY | 1 |
| Cai, HY | 1 |
| Wang, T | 1 |
| Zhao, JC | 1 |
| Sun, P | 1 |
| Yan, GR | 1 |
| Ding, HP | 1 |
| Li, YX | 1 |
| Wang, HY | 1 |
| Zhu, WL | 1 |
| Chen, KX | 1 |
| Joo, K | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Joo, H | 1 |
| Park, W | 1 |
| Yamamoto, T | 1 |
| Moriwaki, Y | 1 |
| Takahashi, S | 1 |
| Suda, M | 1 |
| Agbedana, EO | 1 |
| Higashino, K | 1 |
5 other studies available for benzbromarone and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effects of different doses glimepiride intake on the pharmacokinetics of benzbromarone in rats.
Topics: Animals; Benzbromarone; Diabetes Mellitus, Type 2; Drug Interactions; Rats; Sulfonylurea Compounds; | 2023 |
Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Case-Control Studies; Diabe | 2019 |
Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice.
Topics: 3T3-L1 Cells; Animals; Benzbromarone; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relati | 2013 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |
Two cases in whom pyrazinamide does not inhibit the uricosuric action of benzbromarone.
Topics: Adult; Benzbromarone; Diabetes Mellitus, Type 2; Drug Interactions; Female; Humans; Kidney; Kidney D | 1992 |